MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/jvimsj/aalag107

Медицинская библиотека · Journal of veterinary internal medicine · 2026

Efficacy and safety of canagliflozin in insulin dysregulated horses: a 4-week multi-arm, double-blind, randomized, clinical trial.

Bröjer Johan, Hanche-Olsen Siv, Fintl Constanze, Svonni Elin, Hellings Ingunn Risnes, Müller Cecilia, Lindåse Sanna

СтатьяМногоцентровое исследованиеRandomized Controlled Trial, VeterinaryПеревод в очереди

Аннотация

BACKGROUND

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are promising drugs for treatment of hyperinsulinemia in insulin-dysregulated (ID) horses.

HYPOTHESIS/

OBJECTIVES

Compare short-term effects of the SGLT2 inhibitor canagliflozin versus placebo on glucose and insulin responses during an oral sugar test (OST) and a forage-based feed challenge test (FCT), and to assess adverse effects.

ANIMALS: Forty-two privately owned severely ID horses.

METHODS

Multi-center, randomized, double-blind, placebo-controlled, parallel-group study. Horses were allocated (1:1:1) to receive canagliflozin (0.6 or 1.2 mg/kg PO q24h) or placebo. The study included a 5-day baseline evaluation, a 4-week at-home double-blind treatment period, and a 5-day follow-up evaluation. During each clinical visit, an OST (day 3) and FCT (day 4) were performed to characterize glucose and insulin responses. Adverse effects were recorded. Data are presented as geometric least squares mean (95% CI).

RESULTS

Peak insulin concentrations (μIU/mL) during the OST and the FCT were lower after treatment with canagliflozin 0.6 and 1.2 mg/kg compared with placebo (P ≤ .01); OST: 122.0 (96.6-154.0) and 108.6 (85.6-137.8) vs 288.7 (227.1-366.9) and FCT: 78.3 (37.6-162.9) and 54.2 (25.7-114.5) vs 140.3 (68.5-287.3). Canagliflozin caused a dose-dependent increase in triglyceride concentrations (P ≤ .01). Post-treatment triglyceride concentrations were 0.5 (0.4-0.8), 1.3 (0.9-2.0), and 2.9 (1.9-4.4) mmol/L for placebo, 0.6 mg/kg, and 1.2 mg/kg groups, respectively.

CONCLUSIONS AND CLINICAL

IMPORTANCE

Canagliflozin effectively decreases hyperinsulinemia in ID horses but induces a dose-dependent increase in triglyceride concentrations.

Для цитирования: Bröjer Johan, Hanche-Olsen Siv, Fintl Constanze, Svonni Elin, Hellings Ingunn Risnes, Müller Cecilia, Lindåse Sanna. Efficacy and safety of canagliflozin in insulin dysregulated horses: a 4-week multi-arm, double-blind, randomized, clinical trial.. Journal of veterinary internal medicine. 2026. DOI: 10.1093/jvimsj/aalag107.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.